Paper31335166
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Stewart M and 17 others. JCO Clin Cancer Inform, 2019. Cited by 101 papers, by iCite.
Cite this record
ConductScience Library. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. Papers, record 31335166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31335166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antineoplastic Agents, Immunological | |
| B7-H1 Antigen | |
| Databases, Factual | |
| Electronic Health Records | |
| Female | |
| Humans | |
| Immunotherapy | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasm Staging | |
| Patient Outcome Assessment | |
| United States |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K07 CA188142 | NCI NIH HHS | United States | K07CA188142 | PubMed and NIH | NIH RePORTER |
| K12 CA090628 | NCI NIH HHS | United States | K12CA090628 | PubMed and NIH | NIH RePORTER |
| P30 CA015083 | NCI NIH HHS | United States | P30CA015083 | PubMed and NIH | NIH RePORTER |
| U24 CA171524 | NCI NIH HHS | United States | U24CA171524 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05700344 | SOGUG-AVELUMAB_RWD | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 31335165 | Practical Application of Real-World Evidence in Developing Cancer Therapies. | https://conductscience.org/library/papers/31335165 |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28836267 | When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? | Clin Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28836267 | PubMed |
| 2 | 25848584 | The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. | EGEMS (Wash DC) | 2014 | https://conductscience.org/library/papers/25848584 | PubMed |
| 3 | 30026923 | Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? | F1000Res | 2018 | https://conductscience.org/library/papers/30026923 | PubMed |
| 4 | 24504926 | Cancer recurrence: an important but missing variable in national cancer registries. | Ann Surg Oncol | 2014 | https://conductscience.org/library/papers/24504926 | PubMed |
| 5 | 27662202 | Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. | Blood Cancer J | 2016 | https://conductscience.org/library/papers/27662202 | PubMed |
| 6 | 29756355 | Development and Validation of a High-Quality Composite Real-World Mortality Endpoint. | Health Serv Res | 2018 | https://conductscience.org/library/papers/29756355 | PubMed |
| 7 | 29714575 | Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable. | Ther Innov Regul Sci | 2018 | https://conductscience.org/library/papers/29714575 | PubMed |
| 8 | 30105359 | Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. | JAMA | 2018 | https://conductscience.org/library/papers/30105359 | PubMed |
| 9 | 12663734 | End points and United States Food and Drug Administration approval of oncology drugs. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12663734 | PubMed |
| 10 | 30873729 | An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database. | Pharmacoepidemiol Drug Saf | 2019 | https://conductscience.org/library/papers/30873729 | PubMed |
| 11 | 29423118 | The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. | Oncotarget | 2018 | https://conductscience.org/library/papers/29423118 | PubMed |
| 12 | 28529317 | How much do clinical trials cost? | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/28529317 | PubMed |
| 13 | 28767357 | Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28767357 | PubMed |
Cited by81
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42825071 | Early endocrine diagnoses and subsequent survival after immune checkpoint inhibitor initiation in non-small cell lung cancer: a 180-day landmark cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42825071 | PubMed |
| 42794628 | Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794628 | PubMed |
| 42601535 | Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study. | Support Care Cancer | 2026 | https://conductscience.org/library/papers/42601535 | PubMed |
| 42563022 | The End of 'Pay-and-Hope': Managing Accelerated Approvals with Outcomes-Based Reimbursement in the Era of Routinely Collected Health Data. | Pharmacoeconomics | 2026 | https://conductscience.org/library/papers/42563022 | PubMed |
| 42004488 | Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database. | ESMO Real World Data Digit Oncol | 2026 | https://conductscience.org/library/papers/42004488 | PubMed |
| 41843049 | Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative. | Adv Ther | 2026 | https://conductscience.org/library/papers/41843049 | PubMed |
| 41807852 | Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program. | Drugs Real World Outcomes | 2026 | https://conductscience.org/library/papers/41807852 | PubMed |
| 41593124 | Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/41593124 | PubMed |
| 41450930 | Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41450930 | PubMed |
| 41390939 | The effect of common medications on the efficacy of immune checkpoint inhibitors. | Cancer | 2025 | https://conductscience.org/library/papers/41390939 | PubMed |
| 41277909 | Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies. | J Liq Biopsy | 2025 | https://conductscience.org/library/papers/41277909 | PubMed |
| 41201834 | Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41201834 | PubMed |
| 40884222 | Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. | J Manag Care Spec Pharm | 2025 | https://conductscience.org/library/papers/40884222 | PubMed |
| 40354012 | Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank. | Adv Ther | 2025 | https://conductscience.org/library/papers/40354012 | PubMed |
| 39819032 | Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab. | J Comp Eff Res | 2025 | https://conductscience.org/library/papers/39819032 | PubMed |
| 39551068 | Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/39551068 | PubMed |
| 39365963 | Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non-Small Cell Lung Cancer. | JCO Clin Cancer Inform | 2024 | https://conductscience.org/library/papers/39365963 | PubMed |
| 39146509 | Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy. | JCO Clin Cancer Inform | 2024 | https://conductscience.org/library/papers/39146509 | PubMed |
| 39113428 | Exploring the discrepancies between clinical trials and real-world data: A small-cell lung cancer study. | Clin Transl Sci | 2024 | https://conductscience.org/library/papers/39113428 | PubMed |
| 39102176 | Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations. | Drug Saf | 2024 | https://conductscience.org/library/papers/39102176 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALK | 238 | PubTator's text mining | https://conductscience.org/library/genes/238 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31335166
GET https://conductscience.org/api/papers/v1/31335166/cited_by?page=2